JD Health stock trades at HKD 34.86 as profit rises 32.4 percent

Published on 10/07/2026 at 05:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JD Health stock stood at HKD 34.86 on October 7, 2026, while first-half revenue reached CNY 40.9 billion, up 15.9 percent. Net profit climbed 32.4 percent.

JD Health, KYG5074A1004, Illustration mit AI erstellt.

JD Health stock (ISIN KYG5074A1004) was trading at HKD 34.86 on the Hong Kong Stock Exchange on October 7, 2026, down 0.80 percent from the previous close. The latest operating picture is stronger than the daily move suggests: first-half 2026 net profit rose 32.4 percent to CNY 3.44 billion.

Revenue reaches CNY 40.9 billion

According to iPulse AI, JD Health generated CNY 40.9 billion in revenue in the first half of 2026, an increase of 15.9 percent from the comparable period. The same period produced CNY 3.44 billion in net profit, with profit growth exceeding revenue growth by 16.5 percentage points.

The margin trend is equally important for the valuation debate. Consolidated gross margin reached 26.1 percent in the first half of 2026, compared with 24.8 percent in 2025, while non-IFRS operating margin reached 8.5 percent, according to iPulse AI.

Consensus stays above HKD 60

Analyst expectations remain materially above the Hong Kong quotation. Eulerpool reports a consensus average target of CNY 64.52 from 24 analyst ratings, including 21 Buy ratings, 3 Hold ratings and 0 Sell ratings. The median target is CNY 61.76.

A separate October 3 update from Simply Wall St raised its model fair value from HKD 49.44 to HKD 49.90. The update also identified rising AI and offline expansion costs as constraints on future operating and net margin progress.

Stock trades below yearly high

JD Health's HKD 34.86 price sits within a 52-week range of HKD 31.84 to HKD 71.70 as of October 7, 2026. The HKD 111.9 billion market capitalization and 454,051-share trading volume put the current session into a market context where earnings growth and valuation expectations are moving in different directions.

The company operates an online healthcare platform spanning online pharmacy, medical consultation, telemedicine and health management services, according to iPulse AI. For investors, the key test is whether the 15.9 percent revenue increase can continue to support profit growth while expansion costs remain controlled.